C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction

Cardiovascular Research

Volumn 84, Issue 3, 2009, Pages 479-484

  Devaraj, Sridevi ^a,b   Yun, Jung Mi ^a,b   Adamson, Grete ^a,b   Galvez, Jose ^a,b   Jialal, Ishwarlal ^a,b  

^a Laboratory for Atherosclerosis and Metabolic Research   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

C reactive protein; Dysfunction; Endothelium; ENOS; Glycocalyx; Hyaluronan; Inflammation

Indexed keywords

BETA ACTIN; C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLYCOCALYX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; SUPERNATANT; THICKNESS; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

AORTA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CELL ADHESION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GLYCOCALYX; HEPARITIN SULFATE; HUMANS; HYALURONIC ACID;

EID: 70849095298     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp249     Document Type: Article

References (38)

1. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-519.
2. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007;49:2129-2138.
3. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombo-sis. Circulation 2006;113:2135-2150.
4. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009;52:229-238.
5. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-1441.
6. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
7. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 2007;43:780-791.
8. Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE et al. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis 2008;201:318-325.
9. Jialal I, Verma S, Devaraj S. Inhibition of endothelial nitric oxide synthase by C-reactive protein. Clin Chem 2009;55:206-208.
10. Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009; doi:10.1016/j.atherosclerosis. 2009.02.002, Published online ahead of print February 12.
11. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 2007;9:121-167.
12. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES. The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol 2005;16:507-511.
13. Weinbaum S, Zhang X, Han Y, Vink H, Cowin SC. Mechanotransduction and flow across the endothelial glycocalyx. Proc Natl Acad Sci USA 2003;100: 7988-7995.
14. Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ Res 2003;93:e136-e142.
15. Thi MM, Tarbell JM, Weinbaum S, Spray DC. The role of the glycocalyx in reorganization of the actin cytoskeleton under fluid shear stress: a 'bumper-car' model. Proc Natl Acad Sci USA 2004;101:16483-16488.
16. Henry CB, Duling BR. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol 1999;277:H508-H514.
17. Constantinescu AA, Vink H, Spaan JA. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterios-cler Thromb Vasc Biol 2003;23:1541-1547.
18. van den Berg BM, Spaan JA, Rolf TM, Vink H. Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am J Physiol Heart Circ Physiol 2006;290:H915-H920.
19. Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 1997; 100:867-874.
20. Lewis JC, Taylor RG, Jones ND, St Clair RW, Cornhill JF. Endothelial surface characteristics in pigeon coronary artery atherosclerosis. I. Cellular alterations during the initial stages of dietary cholesterol challenge. Lab Invest 1982;46:123-138.
21. Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006;55:1127-1132.
22. Nieuwdorp M, Holleman F, de Groot E, Vink H, Gort J, Kontush A et al. Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. Diabetologia 2007;50:1288-1293.
23. Dasu MR, Devaraj S, Du Clos TW, Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res 2007;48:509-512.
24. van den Berg BM, Vink H, Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ Res 2003;92:592-594.
25. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-860.
26. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al., Pra-vastatin or Atorvastatin Evaluation, Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
27. Nitert MD, Chisalita SI, Olsson K, Bornfeldt KE, Arnqvist HJ. IGF-I/insulin hybrid receptors in human endothelial cells. Mol Cell Endocrinol 2005; 229:31-37.
28. Devaraj S, Davis B, Simon SI, Jialal I. CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol 2006;291:H1170-H1176.
29. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107:398-404.
30. Schwedler SB, Kuhlencordt PJ, Ponnuswamy PP, Hatiboglu G, Quaschning T, Widder J et al. Native C-reactive protein induces endo-thelial dysfunction in ApoE2/2 mice: implications for iNOS and reactive oxygen species. Atherosclerosis 2007;195:e76-e84.
31. Schwartz R, Osborne-Lawrence S, Hahner L, Gibson LL, Gormley AK, Vongpatanasin W et al. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res 2007;100:1452-1459.
32. Guan H, Wang P, Hui R, Edin ML, Zeldin DC, Wang DW. Adeno-associated virus-mediated human C-reactive protein gene delivery causes endo-thelial dysfunction and hypertension in rats. Clin Chem 2009;55: 274-284.
33. Singh U, Devaraj S, Jialal I. C-reactive protein stimulates myeloperoxi-dase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem 2009;55:361-364.
34. Devaraj S, Dasu MR, Singh U, Rao LV, Jialal I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 2009;203:67-74.
35. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 releaseinWistarrats.JLipid Res2008;49:1015-1023.
36. Bisoendial RJ, Kastelein JJ, Peters SL, Levels JH, Birjmohun R, Rotmans JI et al. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res 2007;48:952-960.
37. Vink H, Constantinescu A, Spaan J. Oxidized lipoproteins degrade the endothelial surface layer. Circulation 2000;101:1500-1502.
38. Henry C, Duling B. TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol 2000;279:H2815-H2823.